Laidlaw Downgrades Intercept Pharmaceuticals (ICPT) to Sell
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff weighs down Wall Street as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Tech selloff weighs down Wall Street as bond yields climb
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Francisco Partners to acquire Weave Communications for $650M
Intercept Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
August 4, 2016 7:05 AM EDTOcaliva® (obeticholic acid or OCA) approved by the FDA under the accelerated approval pathway on May 27, 2016Net Ocaliva 2Q sales of $75,000 shipped to patients, $2.7 million recorded as deferred revenueREGENERATE NASH trial targeted to complete enrollment for interim analysis in 1H17
Conference call scheduled for 8:30 am ET today      Â
NEW YORK, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel... More
